Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552227 · ClinicalTrials.gov registry record · Phase 1
Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Chromaderm.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00552227 is a Phase 1 study that has completed, run by Chromaderm. The registered enrollment target is 48 participants.
The verdict
NCT00552227, a Phase 1 study, has completed, sponsored by Chromaderm.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ruboxistaurin can reduce blood vessel inflammation associated with diabetes.
Interventions
- OTHER placebo
- DRUG ruboxistaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2002-09 |
| Est. Completion | 2005-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00552227
The ClinicalTrials.gov registry entry for NCT00552227 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chromaderm, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00552227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00552227 about?
NCT00552227 is a clinical study titled "Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to determine whether ruboxistaurin can reduce blood vessel inflammation associated with diabetes.
What is the current status of trial NCT00552227?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2002-09. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00552227?
The interventions under investigation include: placebo (OTHER), ruboxistaurin (DRUG).
Who is sponsoring clinical trial NCT00552227?
This trial is sponsored by Chromaderm, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.